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Abstract
Cell models of mitochondrial complex I (CI) deﬁciency display activation of glycolysis to compensate for the loss in
mitochondrial ATP production. This adaptation can mask other relevant deﬁciency-induced aberrations in cell
physiology. Here we investigated the viability, mitochondrial morphofunction, ROS levels and ATP homeostasis of
primary skin ﬁbroblasts from Leigh Syndrome (LS) patients with isolated CI deﬁciency. These cell lines harbored
mutations in nuclear DNA (nDNA)-encoded CI genes (NDUFS7, NDUFS8, NDUFV1) and, to prevent glycolysis
upregulation, were cultured in a pyruvate-free medium in which glucose was replaced by galactose. Following
optimization of the cell culture protocol, LS ﬁbroblasts died in the galactose medium, whereas control cells did not. LS
cell death was dose-dependently inhibited by pyruvate, malate, oxaloacetate, α-ketoglutarate, aspartate, and
exogenous NAD+ (eNAD), but not by lactate, succinate, α-ketobutyrate, and uridine. Pyruvate and eNAD increased the
cellular NAD+ content in galactose-treated LS cells to a different extent and co-incubation studies revealed that
pyruvate-induced rescue was not primarily mediated by NAD+. Functionally, in LS cells glucose-by-galactose
replacement increased mitochondrial fragmentation and mass, depolarized the mitochondrial membrane potential
(Δψ), increased H2DCFDA-oxidizing ROS levels, increased mitochondrial ATP generation, and reduced the total cellular
ATP content. These aberrations were differentially rescued by pyruvate and eNAD, supporting the conclusion that
these compounds rescue galactose-induced LS cell death via different mechanisms. These ﬁndings establish a cell-
based strategy for intervention testing and enhance our understanding of CI deﬁciency pathophysiology.
Introduction
Oxidative phosphorylation (OXPHOS) is carried out by
ﬁve protein complexes (CI-CV) and constitutes a prime
source of mitochondrial ATP1. OXPHOS dysfunction and
isolated CI deﬁciency (OMIM 252010) is often associated
with Leigh Syndrome (LS), a rare metabolic disorder with
poorly understood pathophysiology2–6. Functionally, CI
couples the transfer of electrons from NADH to oxidized
ubiquinone-10 to the transport of H+ from the
mitochondrial matrix across the mitochondrial inner
membrane (MIM). This process provides the electron
transport chain (ETC) with reducing equivalents to sus-
tain a trans-MIM pH gradient (ΔpH) and electrical
potential (Δψ). Moreover, CI action allows operation of
the tricarboxylic acid (TCA) cycle by NADH-to-NAD+
recycling7–10. We previously demonstrated that primary
skin ﬁbroblasts of pediatric LS patients exhibit disturbed
calcium/ATP homeostasis11, partial Δψ depolarization12,
altered mitochondrial morphology13, and increased reac-
tive oxygen species (ROS) levels14. However, we neither
detected increased lipid peroxidation nor alterations in
thiol redox state in LS cells14. It was hypothesized that
mitochondrial (CI-mediated) NADH recycling is required
to prevent “reductive stress” (as opposed to “oxidative
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stress”) and allow cell proliferation9. Various CI deﬁciency
models display an apparent reduction in NAD+/NADH
ratio14–16, compatible with the key role of CI in oxidizing
NADH to NAD+17 and supporting the reductive stress
hypothesis. In primary skin ﬁbroblasts, the free cytosolic
NAD+/NADH ratio is coupled to the lactate/pyruvate (L/
P) ratio8,18. Compatible with the reductive stress idea,
patients with CI deﬁciency displayed a mild/severe lactic
acidemia paralleled by an increased L/P ratio in the cor-
responding skin ﬁbroblasts19. In CI-inhibited human skin
ﬁbroblasts and other cell models of CI deﬁciency a parallel
increase in lactate production and glycolytic ﬂux was
demonstrated15,20–23. Although the latter is important to
sustain cell viability, it might prevent triggering or inter-
fere with the detection of other relevant consequences of
CI deﬁciency24,25. Here we studied the cellular effects of
genetic CI deﬁciency by comparing control and LS patient
primary skin ﬁbroblasts cultured in (pyruvate-free)
glucose-containing or galactose-containing media. The
latter enters glycolysis via the Leloir pathway at a much
slower rate than glucose, preventing ATP production via
rapid glucose-to-pyruvate conversion26,27. We demon-
strate that glucose-by-galactose replacement speciﬁcally
induces the death of LS ﬁbroblasts, and that this dead is
rescued by pyruvate and exogenous NAD+ (eNAD) via
different mechanisms.
Materials And methods
Cell lines
Fibroblasts were obtained following informed parental
consent and according to the relevant Institutional Review
Boards from skin biopsies of healthy individuals and
various Leigh Syndrome (LS) patients with isolated
complex I (CI) deﬁciency (OMIM 252010). These cell
lines were previously fully characterized at the genetic,
biochemical and cellular level in our group (reviewed in
ref. 39). Control cell lines included: #CT5120 (“CT1”),
#CT5119 (“CT2”), and #CT5118 (“CT3”), which all dis-
played a similar and normal phenotype during their pre-
vious characterization (reviewed in ref. 39). Patient cell
lines harbored mutations in various genes encoding CI
structural subunits: #P5175 (“S7”, NDUFS7-V112M
mutation), #P6603 (“S8”, NDUFS8-R94C mutation), and
#P5866 (“V1”, NDUFV1-R59X/T423M mutations). S8
cells display a very low residual CI activity (i.e., 18% of the
lowest control value) whereas this activity is higher for S7
(68%) and V1 (64%) ﬁbroblasts13. Fibroblasts were cul-
tured in Medium 199 (M199; #22340–020; Thermo Fisher
Scientiﬁc, Waltham, MA, USA) in a humidiﬁed atmo-
sphere (95 air, 5% CO2) at 37 °C. This medium contained
no pyruvate, 25 mM HEPES, 5.5 mM D-glucose, 0.7 mM L-
glutamine, and 0.05 mM phenol red. To this medium was
added: 10% (v/v) Fetal Bovine Serum (FBS; #758093;
Greiner Bio-One, Kremsmünster, Austria), 100 IU/ml
penicillin/streptomycin (#30–002-CI; Corning, NY, USA).
Cells were passaged every 4–5 days when reaching 90%
conﬂuence by trypsinization (#15400054; Corning) and
were mycoplasma negative (Mycoalert® mycoplasma
detection kit; Lonza, Allendale, NJ, USA).
Preparation of glucose and galactose media
As a starting point we used DMEM without glucose,
pyruvate, glutamine and phenol red (#A1443001; Thermo
Fisher). From this DMEM a “glucose medium” was pre-
pared by adding 5.5 mM glucose (#G8270; Sigma-Aldrich,
St. Louis, MO, USA). Similarly, a “galactose medium” was
prepared by adding 5.5 mM galactose (#G0750, Sigma-
Aldrich). To both the glucose/galactose media was added:
1 mM L-glutamine (GlutaMAX®; #35050061; Thermo
Fisher), 10% (v/v) dialyzed Fetal Bovine Serum (FBS;
#26400044; Thermo Fisher), 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES; #15630080;
Thermo Fisher), 100 IU/ml penicillin/streptomycin
(#30–002-CI; Corning), and 0.05 mM Phenol Red (#3532;
Sigma-Aldrich). Glucose and galactose media were stored
at 4 °C in the dark for a maximum of 1 month.
Medium additions
In certain experiments (one of) the following com-
pounds was/were added to the medium: sodium pyruvate
(#11360070, Life Technologies, Carlsbad, CA, USA), L-
aspartic acid (#A7219, Sigma-Aldrich), 2-ketobutyric acid
(#K401, Sigma-Aldrich), oxaloacetic acid (#O4126,
Sigma-Aldrich), sodium L-lactate (#L7022, Sigma-
Aldrich), L-(-)-malic acid (#M1000, Sigma-Aldrich),
sodium succinate dibasic hexahydrate (#S9637, Sigma-
Aldrich), dimethyl α-ketoglutarate (#349631, Sigma-
Aldrich), uridine (#U3003, Sigma-Aldrich), β-
nicotinamide adenine dinucleotide hydrate (#43410,
Sigma-Aldrich), Oleamide (#O2136, Sigma-Aldrich)
These compounds were dissolved directly in the medium
after which its pH was adjusted to 7.2 with NaOH. Media
were freshly prepared prior to each experiment.
Cell functional and viability analysis
Cells were suspended in M199 culture medium, seeded
in black 96-well plates (#655090, Greiner Bio-one) at a
density of 2500 cells/well, and incubated overnight in a
humidiﬁed atmosphere (95 air, 5% CO2) at 37 °C. On the
next day, M199 culture medium was removed, cells were
washed twice during 1min with PBS and glucose or
galactose medium was added. Then, the cells were cul-
tured in these media and analyzed at 24 h (functional
analysis) and 96 h (cell viability analysis).
Live-cell high-content microscopy
Fluorescence microscopy images were acquired from
96-well plates using a BD Pathway 855® High-Content
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Bioimager (Becton Dickinson, Franklin Lakes, NJ, USA)
using a protocol described previously28. For viability
analysis, cells were stained with (a combination of)
Calcein-AM (#65–0853–39; Thermo Fisher) and Hoechst
33258 (#94406, Invitrogen). Calcein-AM is membrane-
permeable and accumulates in the cytosol upon esterase-
mediated cleavage of its AM (acetoxymethyl) ester tail.
Hoechst 33258 is also membrane-permeable and binds to
the AT base pairs in the minor groove of double-stranded
DNA, which greatly increases its ﬂuorescence signal. For
integrated analysis of cellular and mitochondrial mor-
phological/functional parameters (“morphofunction”;
Table S1), cells were co-stained with Calcein-AM,
Hoechst 33258, and TMRM (Tetramethyl rhodamine
methyl ester, #T668, Invitrogen). The latter is a ﬂuor-
escent lipophilic cation that accumulates in the mito-
chondrial matrix depending on the magnitude of the
mitochondrial membrane potential (Δψ). Importantly,
under our experimental conditions TMRM operated in
non-quenching mode and was present in the medium
during image acquisition28. Calcein, Hoechst, and TMRM
images were quantiﬁed as described in detail previously28.
Quantiﬁcation of total cellular ATP and NAD+ content
Using a ×10 objective (UPlanSApo, NA 0.4, Olympus,
Leiderdorp, The Netherlands), 96-well plates were imaged
and the total number of Calcein-positive pixels (“Casum”)
was determined from the center of each well (2×2 image
montage; 4 images in total) by live-cell high-content
microscopy (see above). Next, the total cellular ATP
content was determined using the CellTiter-Glo® Lumi-
nescence Cell Viability Assay according to the manu-
facturer’s protocol (#G7570, Promega Corporation,
Madison, WI, USA). Luminescence signals were quanti-
ﬁed using a scanning microplate reader (FLUOstar
Omega®, BMG Labtech, Cary, NC, USA). This signal was
divided by Casum for each well to normalize for the total
cell volume in each well. The latter is possible given the
ﬂat morphology of the ﬁbroblasts (i.e., their dimensions in
the XY direction greatly exceed their height in the Z-
direction;29). In certain experiments, cells were pre-
incubated for 20min with 10 µM of Oligomycin A
(#O4876, Sigma-Aldrich) prior to ATP quantiﬁcation20.
Total cellular NAD+ content was determined using the
NAD/NADH-Glo® Luminescence Assay (#G9071, Pro-
mega) according to the manufacturer’s protocol and
quantiﬁed as described for the ATP measurement.
Reactive oxygen species measurement
The levels of cellular reactive oxygen species (ROS)
were measured in 96-well plates by quantifying the oxi-
dation of two ROS reporter molecules:30–32 5-(and-6)-
chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate
(CM-H2DCFDA, #C6827, Thermo Fisher) and
Hydroethidine (HEt, #D11347, Thermo Fisher). To this
end, the cells were stained in DMEM medium
(#A1443001; Thermo Fisher), which was supplemented
with 10 mM HEPES (#15630080; Thermo Fisher) and
contained either CM-H2DCFDA (1 µM) or HEt (10 µM)
for 30min (37 °C, 5% CO2) in the dark. After this incu-
bation, cells were washed twice with and placed in Dul-
becco’s phosphate-buffered saline (DPBS containing
calcium and magnesium, #14040133, Thermo Fisher).
Next, ﬂuorescence signals were visualized using the high-
content microscopy system described above (2×2 image
montage; 4 images in total) using a x20 objective (UApo/
340, NA 0.75, Olympus). Following acquisition, each
image (RAW) was processed using the rolling ball algo-
rithm28 with a feature width of 80 pixels to generate a
background (BG) image. Next, the BG image was sub-
tracted from the RAW image to obtain a background-
corrected (COR) image. Noise pixels were removed from
the COR image using a median ﬁlter (MED, 3×3 kernel, 2
passes). Then the image was thresholded using a cut-off of
20 gray values yielding a binary (BIN) image. The latter
was combined with the COR image using a Boolean AND
operation28 to obtain a masked (MSK) image. In the latter
image, the average ﬂuorescence intensity was quantiﬁed
by dividing the integrated pixel intensity (gray value) by
the total number of pixels. This parameter is computa-
tionally equivalent to CaIOD/Casum (Table S1) and
reﬂects the average cellular ﬂuorescence intensity of the
ROS reporter molecule.
Data analysis
Image visualization, processing and quantiﬁcation was
carried out using Image Pro Plus® software (Media
Cybernetics, Rockville, MD, USA) and custom MATLAB®
algorithms (Mathworks, Natick, MA., USA), as described
in detail previously28. Data visualization and analysis was
performed using Origin Pro® (OriginLab, Northampton,
MA, USA) and Graphpad PRISM® software (Graphpad
Software, San Diego, CA, USA). The number of inde-
pendent experiments and replicates are indicated by N
and n, respectively. Unless stated otherwise, data from
multiple experiments is presented as the mean ± standard
error of the mean (SEM) and statistical signiﬁcance was
assessed using an independent two-population Student’s
t-test with Bonferroni correction (*P < 0.05; **P < 0.01;
***P < 0.001).
Results
Galactose speciﬁcally induces death of LS ﬁbroblasts in a
time-dependent manner
Fibroblasts from control subjects (CT1, CT2, CT3) and
LS patients with isolated CI deﬁciency (S7, S8, V1) were
routinely cultured in glutamine-containing DMEM with-
out pyruvate to which 5.5 mM glucose or galactose was
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added. Viability analysis revealed that control cells pro-
liferated in glucose and galactose medium (Fig. 1b),
whereas LS cells proliferated in glucose medium but died
in galactose medium (Fig. 1a). CT1 and LS cells gradually
decreased in size in glucose and galactose medium
(Fig. 1d). These results demonstrate that glucose-by-
galactose replacement speciﬁcally reduces the viability of
LS cells relative to CT1 cells in a time-dependent manner.
However, performing experiments over a time course of
18 months (Table S2) revealed that S8 patient cells
invariably died in galactose medium, whereas death was
variably induced in S7 and V1 cells. A correlation was
observed between the time point at which a freshly pre-
pared galactose medium was used for the ﬁrst time and a
change in the galactose-induced killing efﬁciency (Fig. S5).
Since a medium change might affect cell growth, we
determined whether the LS cell seeding density affected
their galactose-induced killing at 96 h. Higher seeding
densities protected LS ﬁbroblasts against galactose-
induced cell death (Fig. 2a). Therefore, we routinely see-
ded 2500 cells/well and only analyzed experiments where
glucose-by-galactose replacement signiﬁcantly reduced LS
cell viability. This yielded consistent results (Fig. 2b),
allowing cell functional and viability analyses (Fig. 2c).
Given the similar response to galactose within the control
and LS patient cell group (Fig. 2b) we compared CT1 with
average LS cell data in the remainder of the study (the full
dataset is presented in the Supplement, as indicated in the
ﬁgure legends).
Galactose-induced death of LS ﬁbroblasts is rescued by
speciﬁc metabolites in an oleamide-sensitive manner
Galactose-induced LS cell death was dose-dependently
inhibited by pyruvate in the presence of glutamine and
vice versa (Fig. 2d, e). Supplementation of the galactose
medium with malate, oxaloacetate, α-ketoglutarate or
aspartate also (partially) rescued LS cell death (Fig. 2f, g).
Lactate, succinate, α-ketobutyrate or uridine displayed no
rescue (Fig. 2f, g). None of the metabolites affected LS cell
viability in glucose medium (Fig. S7A). Various rescuing
metabolites (e.g., pyruvate, oxaloacetate, α-ketoglutarate)
increased cellular NAD+ content (iNAD; Fig. 3a).
Although α-ketobutyrate also increased iNAD (Fig. 3a),
galactose-induced LS cell death was not rescued (Fig. 2g).
This demonstrates that the rescuing effects of the above
metabolites are not unequivocally linked to increased
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iNAD levels. Next, we evaluated the effect of extracellular
NAD+ (eNAD) on iNAD33 and cell viability. Adding
eNAD to the galactose medium increased iNAD (Fig. 3b)
and rescued galactose-induced LS cell death (Fig. 3c, d).
This rescue was prevented by oleamide (Fig. 3e), an
inhibitor of gap-junction hemichannel-mediated NAD+
entry34. These ﬁndings demonstrate that eNAD applica-
tion increases iNAD and inhibits galactose-induced death
of LS cells via an oleamide-sensitive mechanism.
Rescue of galactose-induced death of LS ﬁbroblasts by
eNAD is enhanced by pyruvate
Supplementation with eNAD increased iNAD levels to a
greater extent than pyruvate supplementation (Fig. 3a, b).
However, pyruvate rescued galactose-induced LS cell
death to a greater extent than eNAD (e.g., Figs. 2g, 3d, e).
Combination experiments demonstrated that, in the
absence of pyruvate, eNAD concentrations up to 1mM
partially rescued galactose-induced LS cell death (Fig. 4;
red line). By itself, pyruvate inhibited galactose-induced
LS cell death to a greater extent than eNAD (Fig. 4; dark
gray bars vs. red line). Moreover, rescue was always larger
for pyruvate+ eNAD than for eNAD alone (Fig. 4; light
gray bars vs. red line). In contrast, pyruvate-induced res-
cue was not stimulated by the presence of eNAD. These
results suggest that the rescue of galactose-induced LS
cell death by pyruvate is not primarily due to its iNAD-
increasing effect.
Mitochondrial morphofunctional analysis demonstrates
differential effects of pyruvate and eNAD
High-content microscopy analysis (Fig. 5a) of TMRM/
Calcein/Hoechst-stained cells28 was applied to analyze
mitochondrial morphology and function (“morphofunc-
tion”). This yielded 44 descriptor values (Table S1), which
were normalized to the glucose condition and visualized
using a heatmap (Fig. 5b). Exploratory analysis (Fig. S11)
revealed that: (i) mitochondrial morphofunction is dif-
ferentially affected by galactose in CT1 and LS ﬁbroblasts,
and (ii) the galactose-induced phenotypic differences
between CT1 and LS cells disappear upon supplementa-
tion with eNAD, but not pyruvate. Regression analysis
(Fig. S11C-D) was used to highlight the descriptors most
differentially altered between CT1 and LS cells (Fig. 5b;
red characters). In glucose medium LS cells contained a
larger number of mitochondria (Nc) than CT1 cells (Fig.
S11C). This difference was enhanced by galactose treat-
ment (Fig. 5c). Pyruvate and eNAD supplementation
inhibited the galactose-induced Nc increase in LS cells
but not in CT1 cells (Fig. 5c). In glucose medium, the total
mitochondrial area per cell (Amt) was higher in LS cells
than in CT1 cells and this difference was enhanced by
galactose treatment (Fig. 5d). Pyruvate supplementation
did not prevent the galactose-induced increase of Amt in
LS and CT1 cells, whereas eNAD was effective in LS cells
but not in CT1 cells (Fig. 5d). Adding eNAD to the
galactose medium increased various descriptors (Dstdv,
Dmax, Dmin, and Dm) in LS but not in CT1 cells
(Fig. S11E). These parameters are all related to the
TMRM ﬂuorescence intensity (Table S1), with Dm
representing the average mitochondrial TMRM ﬂuores-
cence. In glucose medium, LS cells displayed a lower Dm
than CT1 cells, indicating a less negative Δψ (Fig. 5e).
Galactose treatment in the absence/presence of pyruvate
did not affect this difference (Fig. 5e). In LS cells but not
CT1 cells, eNAD but not pyruvate supplementation
increased Dm, suggesting that eNAD partially restored
Δψ (Fig. 5e).
Pyruvate and eNAD reduce the levels of CM-H2DCFDA-
oxidizing ROS
Extracellular pyruvate displays antioxidant properties in
human cells35–38. In glucose medium, LS cells displayed
higher levels of CM-H2DCFDA- and HEt-oxidizing ROS
than CT1 cells (Fig. 6a, b). Galactose treatment increased
CM-H2DCFDA oxidation to a similar level in CT1 and LS
cells (Fig. 6a) without affecting HEt oxidation (Fig. 6b).
Similarly, pyruvate and eNAD lowered CM-H2DCFDA
(see ﬁgure on previous page)
Fig. 2 The viability of LS ﬁbroblasts is reduced in galactose medium in a cell density-dependent manner and rescued by speciﬁc
metabolites. a Effect of cell seeding density on the galactose-induced reduction in viability of LS cells (S7, S8, V1; measured at 96 h; N= 1, n= 8).
b Speciﬁcity of the galactose-induced reduction in viability (2500 cells seeded; measured at 96 h; N= 3, n ≥ 12) for LS cells relative to CT cells (CT1,
CT2, CT3). c Experimental protocol used in this study to quantify the effects of galactose and other treatments on control and LS cells. d Dose-
dependent rescue of the galactose-induced reduction in viability of LS cells (S7, S8, V1) at 96 h by pyruvate in the presence of a constant glutamine
concentration (N= 3, n ≥ 9). The EC50 value was determined by ﬁtting a Hill equation to the data (R2= 0.97). e Same as d, but now for the dose-
dependent effect of glutamine in the presence of a constant pyruvate concentration (N= 3, n ≥ 18). The EC50 value was determined by ﬁtting a Hill
equation to the data (R2= 0.98). f Rescuing effect of speciﬁc metabolites on the galactose-induced reduction in LS cell viability (96 h; Calcein MSK
images for patient S7 are shown as a typical example): sodium pyruvate (10 mM), sodium L-lactate (10 mM), sodium succinate dibasic hexahydrate
(10 mM), L-(-)-malic acid (10 mM), oxaloacetic acid (10 mM), dimethyl α-ketoglutarate (10 mM), 2-ketobutyric acid (10 mM), L-aspartic acid (15 mM),
and uridine (1 mM). The “+ ” conditions reﬂect combined galactose+metabolite treatment. g Quantiﬁcation of the rescuing effect of the
metabolites (N= 3, n ≥ 18) in LS patient cells (S7, S8, V1) at 96 h (N= 3, n ≥ 18). Statistics: *P < 0.05, *P < 0.01, ***P < 0.001, relative to the marked
conditions (a, b, c). Results for the individual cell lines are presented in Fig. S6, S7
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oxidation (Fig. 6a) without affecting HEt oxidation
(Fig. 6b). In S8 cells the glutathione precursor N-
acetylcysteine (NAC) prevented galactose-induced LS
cell death, whereas the vitamin E-derivative Trolox (6-
hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid)
was ineffective (Fig. 6c, d). These results suggest that
galactose-induced cell death co-involves CM-H2DCFDA-
oxidizing and NAC-sensitive ROS.
Cellular ATP content decreases in galactose medium and is
normalized by eNAD but not by pyruvate in LS cells
Pyruvate and eNAD differentially affected Δψ in
galactose-cultured LS cells (Fig. 5e), potentially impacting
on mitochondrial ATP production. In glucose medium,
the ATP content of LS ﬁbroblasts exceeded that of
CT1 cells (Fig. 7a). Glucose-by-galactose replacement
reduced ATP content to a greater extent in LS cells than
in CT1 cells (Fig. 7a). In both CT1 and LS cells, eNAD
supplementation normalized the galactose-induced
reduction in ATP content, whereas pyruvate did not
(Fig. 7a). Preventing mitochondrial ATP production by
the FoF1-ATPase (CV) inhibitor Oligomycin A (OLI)
reduced the ATP content of CT1 and LS cells under all
conditions (Fig. 7b). This demonstrates that mitochon-
drial ATP production is active. In glucose medium,
quantiﬁcation of this ATP reduction revealed that
mitochondria contribute twofold less to total ATP levels
in LS cells than in CT1 cells (Fig. 7c). Given their higher
ATP level (Fig. 7a; white bars), this suggests that glycolysis
is more active in LS cells. Galactose treatment induced a
threefold and sixfold increase in the mitochondrial con-
tribution to total ATP content in CT1 and LS cells,
respectively (Fig. 7c). Addition of eNAD did not affect the
mitochondrial ATP contribution in CT1 but further
increased this parameter in LS cells (Fig. 7c).
Discussion
Activation of glycolysis during CI dysfunction can mask
deﬁciency-induced aberrations in cell physiology (Fig. 8a).
Here we prevented this activation by culturing CT and LS
ﬁbroblasts in pyruvate-free media containing galactose. In
glucose medium, LS ﬁbroblasts exhibited a partially
depolarized Δψ, increased HEt and H2DCFDA oxidation
and altered mitochondrial morphology (Fig. 8b), compa-
tible with our previous ﬁndings39. In addition, we here
demonstrate that LS cells display a higher ATP content
than CT1 ﬁbroblasts and derive less of their total ATP
from mitochondria. This suggests a mechanism in which:
(i) the CI-deﬁcient state stimulates glycolytic lactate and
ATP generation, thereby reducing the mitochondrial
contribution to cellular ATP content, and (ii) NADH
levels increase as the combined result of glycolytic
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upregulation and hampered mitochondrial NADH-to-
NAD+ conversion by CI (Fig. 8a).
Galactose induces speciﬁc death of LS cells
Glucose-by-galactose replacement induced the speciﬁc
death of LS ﬁbroblasts without affecting CT1 cell viability,
providing that a sufﬁciently low cell seeding density was
used. We speculate that cell-cell adhesion might play a
role in counteracting the galactose effect40 and/or death-
suppressing pathways might become activated at high cell
densities41. Galactose treatment invariably reduced the
viability of S8 ﬁbroblasts with a low residual CI activity
(18% of lowest control value) whereas variable results
were obtained with S7 and V1 cells displaying a moderate
reduction in CI activity (68–64%). This is compatible with
previous ﬁndings26 and suggests a mechanism in which
the degree of CI deﬁciency determines the extent of
compensatory glycolysis activation and, as a consequence,
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the cellular sensitivity to glucose-by-galactose replace-
ment. Indeed, CI inhibition dose-dependent increased
lactate production in mouse ﬁbroblasts42 and NADH-
cytochrome c reductase activity inversely correlated with
the L/P ratio in primary ﬁbroblasts from OXPHOS-
deﬁciency patients (linear correlation: R=−0.61; p=
0.01; data from ref. 19.
Pyruvate rescues galactose-induced death of LS cells
Galactose only induced speciﬁc death of LS ﬁbroblasts
in the absence of pyruvate. Since pyruvate is normally
produced by the glycolysis pathway43, this suggests that:
(i) the reduced glycolytic ﬂux in galactose-treated cells
induces pyruvate shortage, and (ii) this pyruvate shortage
is responsible for the speciﬁc galactose-induced death of
LS cells. Pyruvate-mediated rescue of galactose-induced
LS cell death was glutamine-dependent. However,
although glutamine was present in all galactose media it
did not prevent LS cell death in the absence of pyruvate.
In HeLa cells, glutamine fuels OXPHOS-mediated mito-
chondrial ATP production via the TCA cycle, providing
more than half of the ATP in the presence of glucose and
virtually all ATP upon replacing glucose by galactose44. In
addition, inhibition of the mitochondrial pyruvate carrier
in cancer cells activated glutamate dehydrogenase and
rerouted the glutamine metabolism to generate oxaloa-
cetate and acetyl-CoA, thereby sustaining TCA cycle
function45. This situation might also be present in our
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galactose-treated LS cells, where the glycolytic pyruvate
production ﬂux is expected to be low. Alternatively, in
case of OXPHOS-deﬁcient cells with mitochondrial DNA
(mtDNA) mutations, it was proposed that impaired
NADH utilization by the mitochondrial ETC triggers
reductive carbonylation of glutamine in the cytosol cata-
lyzed by malate dehydrogenase 1 46. This study proposed a
mechanism in which reduced mitochondrial NADH
turnover inhibits the mitochondrial malate-aspartate
shuttle (MAS), leading to cytosolic NADH accumula-
tion. The latter then induces cytosolic reductive carbo-
nylation of glutamine, which provides carbons for NADH-
coupled MDH1 and thereby regulates NAD+ redox state
and enhances the activity of the glycolysis enzyme
GAPDH. This then increases glycolytic ﬂux to enhance
ATP production in the cytosol46. However, since this
mechanism requires a highly active glycolysis pathway it is
unlikely that it explains the glutamine-dependence of the
pyruvate rescue of galactose-induced LS cell death
observed in our experiments. Previous evidence suggests
that inhibited cell proliferation during ETC disruption is
rescued by pyruvate supplementation via restoration of
NAD+/NADH balance mediated by lactate dehy-
drogenase in the cytosol9,47. Compatible with this
mechanism, we observed that pyruvate slightly increased
cellular NAD+ content. However, pyruvate also displays
antioxidant activity. Here, pyruvate rescue of galactose-
induced LS cell death was paralleled by normalization of
the galactose-induced increase in CM-H2DCFDA-
oxidizing ROS levels (Fig. 8d). In contrast, the increased
levels of HEt-oxidizing ROS in LS cells were neither sti-
mulated further by galactose treatment nor affected by
pyruvate. This suggests that pyruvate might rescue
galactose-induced LS cell death by lowering the levels of
CM-H2DCFDA-oxidizing ROS. Supporting this idea,
pyruvate protected human ﬁbroblasts against H2O2-
induced cell death, by lowering CM-H2DCFDA-oxidizing
ROS levels and preventing Δψ depolarization48. Related to
this, three other molecules that rescued galactose-induced
LS cell death in the current study (pyruvate, oxaloacetate,
and α-ketoglutarate) also reduced the levels of CM-
H2DCFDA-oxidizing ROS and protected against hydro-
gen peroxide (H2O2)-induced toxicity
37. Similarly, non-
rescuing molecules in the current study (lactate, succi-
nate, malate, and α-ketobutyrate) were also ineffective in
the H2O2-induced toxicity model
37. This suggests that
(part of) the rescuing effects of pyruvate, oxaloacetate, and
α-ketoglutarate is due to their antioxidant properties.
Although glutamine also can act as an (in)direct anti-
oxidant49, its presence in the galactose medium did not
prevent LS cell death. This means that it displays no
antioxidant properties in our experimental system and/or
its medium concentration is too low. Functionally, pyr-
uvate supplementation did not affect Δψ, Nc, Amt or the
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decreased ATP content in galactose-treated CT1 cells
(Fig. 8c). In galactose-treated LS cells, pyruvate slightly
reduced Nc but did not restore Δψ, Amt or cellular ATP
content (Fig. 8c). Therefore we propose that pyruvate
does not rescue galactose-induced LS cell death by
restoring mitochondrial function but by its ability to
prevent the galactose-induced increase CM-H2DCFDA-
oxidizing ROS levels. This means that, under galactose
conditions, pyruvate rescue of LS viability requires TCA
fueling by glutamine to sustain biomolecule synthesis and
cell proliferation44,45.
eNAD rescues galactose-induced death of LS cells
For the metabolites tested in this study, their ability to
rescue the galactose-induced death of LS cells was not
unequivocally paralleled by an iNAD increase. As men-
tioned above, this likely relates to fact that several of these
metabolites also can act as antioxidants (pyruvate, oxa-
loacetate, and α-ketoglutarate). However, supplementa-
tion of the galactose medium with eNAD increased
iNAD33 and dose-dependently rescued LS cells from
galactose-induced death. Oleamide dose dependently and
completely inhibited the eNAD-induced rescue of
galactose-induced death in LS cells, suggests that eNAD
exerts its protective effects by increasing iNAD via gap-
junction hemichannels. Combined treatment with pyr-
uvate and eNAD revealed that pyruvate alone rescued
galactose-induced LS cell death to a larger extent than
eNAD alone. In addition, rescue was always greater for
combined pyruvate and eNAD supplementation than for
eNAD alone. Remarkably, eNAD increased iNAD levels to
a much greater extent than pyruvate. These results sug-
gest that the rescuing effect of pyruvate is not due to its
iNAD-increasing effect, which supports the above con-
clusion that pyruvate prevents galactose-induced LS cell
death by acting as an antioxidant. Similar to pyruvate,
eNAD lowered the galactose-induced increase in CM-
H2DCFDA-oxidizing ROS levels in galactose-treated CT1
(Fig. 8c) and LS cells (Fig. 8d). Although this suggests that
iNAD directly lowers these ROS levels, the latter was not
observed in HeLa cells33. At the functional level, and
similar to pyruvate, eNAD supplementation did not affect
the normal Δψ, the normal HEt oxidation, the moderately
increased number of mitochondria per cell, the moder-
ately increased mitochondrial mass or the moderately
decreased ATP content in galactose-treated CT1 cells
(Fig. 8c). In contrast, eNAD fully restored the galactose-
induced reduction in ATP content of CT1 cells. In the
case of galactose-treated LS cells, and in sharp contrast to
pyruvate, eNAD partially restored the depolarized Δψ and
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exogenous NAD+ (eNAD) supplementation on CT1 cells. For each measured parameter, it is indicated whether both supplements displayed a
common effect (“C”), differential effect (“D”) or no effect (“N”). The glucose condition was reproduced from b. d Same as c, but now for ﬁbroblasts
from Leigh Syndrome (LS) patients with isolated CI deﬁciency. The glucose condition was reproduced from b
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fully restored the galactose-induced reduction in ATP
content (Fig. 8d).
Conclusions
Our results establish a cell-based strategy for interven-
tion testing and analysis of the pathophysiological con-
sequences and adaptive responses in CI deﬁciency. We
propose a mechanism in which pyruvate rescues the
galactose-induced death of LS cells by directly lowering
the levels of CM-H2DCFDA-oxidizing and NAC-sensitive
ROS, during which glutamine (and not pyruvate) is used
for TCA cycle fueling. In the case of eNAD, we conclude
that it rescues galactose-induced death of LS cells by
partially restoring Δψ depolarization and fully normal-
izing their greatly reduced cellular ATP content. This is
compatible with CI-deﬁcient LS cells suffering from
galactose-induced reductive stress. Whether NAD+ low-
ers the levels of CM-H2DCFDA-oxidizing ROS by redu-
cing mitochondrial ROS production or via (indirectly)
acting as an antioxidant remains to be determined.
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